Orexigen Therapeutics (OREX) 5.30 $OREX
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Orexigen Therapeutics Down 17.5% Since SmarTrend Downtrend Call (OREX)
Comtex SmarTrend(R) - Mon Apr 14, 9:15AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 2 weeks, Orexigen Therapeutics has returned 17.45% as of today's recent price of $5.25.
Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
M2 - Thu Apr 10, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2442zl/obesity) has announced the addition of the "Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity" report to their offering. The current market, which is dominated by off-patent orlistat products, is expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from approximately $750m in 2012 to approximately $2.6 billion in 2019 Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and the authors believe that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, the authors expect the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Pipeline - Market Forecasts - Licensing and Co-Development Deals - Appendix Products Mentioned - Cametor, Norgine BV - Contrave, Orexigen Therapeutics - Victoza, Novo Nordisk - Tesofensine (NeuroSearch) For more information visit http://www.researchandmarkets.com/research/2442zl/obesity
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Global Contrave (Obesity) Market 2014 - Forecast and Apportunities to 2022
M2 - Wed Apr 02, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tc6jzb/contrave) has announced the addition of the "Contrave (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Contrave for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Contrave 9 Appendix For more information visit http://www.researchandmarkets.com/research/tc6jzb/contrave
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Shares of OREX Up 14.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 18, 9:18AM CDT
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.76% as of today's recent price of $7.23.
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 9:13AM CDT
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Narrower Loss at Orexigen in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:30AM CDT
Orexigen Therapeutics reported a net loss of 21 cents per share in the fourth quarter of 2013.
Orexigen Therapeutics Reduces Q4 Loss by 34%
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 4:27PM CDT
Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics posted a narrower fourth-quarter loss on the back of lower research and development expenses. For the quarter, Orexigen recorded $857,000 in revenue which is...
Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
PR Newswire - Wed Mar 12, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the fourth quarter and year ended December 31, 2013.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
14.5% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Mar 05, 11:20AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.52% as of today's recent price of $7.22.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Orexigen Therapeutics Down 17.5% Since SmarTrend Downtrend Call (OREX)
Comtex SmarTrend(R) - Mon Apr 14, 9:15AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 2 weeks, Orexigen Therapeutics has returned 17.45% as of today's recent price of $5.25.
Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
M2 - Thu Apr 10, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2442zl/obesity) has announced the addition of the "Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity" report to their offering. The current market, which is dominated by off-patent orlistat products, is expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from approximately $750m in 2012 to approximately $2.6 billion in 2019 Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and the authors believe that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, the authors expect the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Pipeline - Market Forecasts - Licensing and Co-Development Deals - Appendix Products Mentioned - Cametor, Norgine BV - Contrave, Orexigen Therapeutics - Victoza, Novo Nordisk - Tesofensine (NeuroSearch) For more information visit http://www.researchandmarkets.com/research/2442zl/obesity
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Global Contrave (Obesity) Market 2014 - Forecast and Apportunities to 2022
M2 - Wed Apr 02, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tc6jzb/contrave) has announced the addition of the "Contrave (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Contrave for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Contrave 9 Appendix For more information visit http://www.researchandmarkets.com/research/tc6jzb/contrave
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Health Car Sector Equities Technical Insight -- Research on Dynavax Technologies, Forest Laboratories, Orexigen Therapeutics and Endo Inl.
PR Newswire - Fri Mar 21, 9:08AM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
PR Newswire - Wed Mar 19, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), WellCare Health Plans, Inc. (NYSE: WCG), Zogenix, Inc. (NASDAQ: ZGNX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), and XOMA Corporation (NASDAQ: XOMA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Shares of OREX Up 14.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 18, 9:18AM CDT
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.76% as of today's recent price of $7.23.
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 9:13AM CDT
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Narrower Loss at Orexigen in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:30AM CDT
Orexigen Therapeutics reported a net loss of 21 cents per share in the fourth quarter of 2013.
Orexigen Therapeutics Reduces Q4 Loss by 34%
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 4:27PM CDT
Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics posted a narrower fourth-quarter loss on the back of lower research and development expenses. For the quarter, Orexigen recorded $857,000 in revenue which is...
Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended December 31, 2013
PR Newswire - Wed Mar 12, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the fourth quarter and year ended December 31, 2013.
'Mad Money' Lightning Round: Boston Scientific Is a Favorite
at The Street - Wed Mar 12, 5:00AM CDT
Cramer also loves Occidental Petroleum but he's not recommending Bed Bath & Beyond.
Jim Cramer's 'Mad Money' Recap: Silver Lining Playbook
at The Street - Tue Mar 11, 7:04PM CDT
The markets are a healthier place today, even though most investors lost money, Cramer says.
14.5% Return Seen to Date on SmarTrend Orexigen Therapeutics Call (OREX)
Comtex SmarTrend(R) - Wed Mar 05, 11:20AM CST
SmarTrend identified an Uptrend for Orexigen Therapeutics (NASDAQ:OREX) on January 10th, 2014 at $6.30. In approximately 2 months, Orexigen Therapeutics has returned 14.52% as of today's recent price of $7.22.
